CROI 2016 Program at a Glance

Program and Agenda

615 Cancer Versus Tuberculosis Mortality Among HIV-Infected Individuals in Botswana

Session TD-4 Themed Discussion

Room 304/306

1:45 PM-2:45 PM Learning from Experience: Shaping the Future of Antiretroviral Therapy in Sub-Saharan Africa Themed Discussion Leader Tsitsi Mutasa-Apollo, UniversityofZimbabwe,Harare,Zimbabwe 1015 6-Year Retention and Immunological Response to ART by Gender: IeDEAWest Africa ThierryTiendrebeogo 1 ; Juan Burgos-Soto 1 ; Eugene Messou 2 ; AristophaneTanon 3 ;Vivian Kwaghue 4 ; Marcel Zannou 5 ; Albert Minga 6 ; Nathalie De Rekeneire 1 ; Francois Dabis 7 ; Renaud Becquet 1 1 INSERMU897,Bordeaux,France; 2 CePReF,ACONDA,Abidjan,Côte d'Ivoire; 3 CHUdeTreichville,Abidjan,Côted'Ivoire; 4 UnivofAbuja TeachingHosp,Abuja,Nigeria; 5 CntrdePriseenChargedesPersonnes VivantAvec leVIH,CHNU,Cotonou,Benin; 6 CntrMédicaldeSuivide DonneursdeSang/CNTS/PRIMO-CI,Abidjan,Côted'Ivoire; 7 INSERM U897, ISPED,UnivdeBordeaux,Bordeaux,France 1021 Declining Mortality in Patients on ART Lost to Follow- up in Sub-Saharan Africa Matthias Egger 1 ; Anne Mooser 1 ; Kathrin Zürcher 1 ; Denis Nash 2 ; Olga Tymejczyk 2 ; Margaret Couvillon 1 ; for the IeDEA and MESH Consortia 1 UnivofBern,Bern,Switzerland; 2 SchofPH,CityUnivofNewYork,New York,NY,USA 1029 Comparing Adherence Methods: Which Best Predicts Virological and Resistance Outcome? Catherine Orrell 1 ; Karen Cohen 1 ; Rory Leisegang 1 ; David R. Bangsberg 2 ; Gary Maartens 1 ; RobinWood 1 1 UnivofCapeTown,CapeTown,SouthAfrica; 2 HarvardMedSch,Boston, MA,USA 1027 High Rate of Viral Suppression in Late Mortality on First-Line ART in Uganda/Zimbabwe 1 MedRsrCouncilClinicalTrialsUnitatUnivCollLondon,London,UK; 2 MedRsrCouncil/UgandaVirusRsr InstUgandaRsrUnitonAIDS, Entebbe,Uganda; 3 SchofPopHlth,UnivofQueensland,Herston, Australia; 4 AfricaCntr forHlthandPopStudies,Mtubatuba,SouthAfrica 1030 Adherence Predicts Failure on PI-Based Second-Line ART in Rural South Africa Dami A. Collier 1 ; Kathy Baisley 2 ; Dickman Gareta 3 ; Deenan Pillay 3 ; Ravindra K. Gupta 1 1 UnivCollLondon,London,UK; 2 LondonSchofHygiene&TropMed, London,UK; 3 AfricaCntr forHlthandPopStudies,Mtubatuba,South Africa David I. Dolling 1 ; Pontiano Kaleebu 2 ; Peter Nkurunziza 2 ; Moira Spyer 1 ; Charles Gilks 3 ; Deenan Pillay 4 ; Ruth Goodall 1 ; for the DART Virology Group

Scott Dryden-Peterson 1 ; Gita Suneja 2 ; Heluf Medhin 3 ; Memory Bvochora-Nsingo 4 ; Mukendi K. Kayembe 5 ; NeoTapela 3 ; Shahin Lockman 1 1 BrighamandWomen'sHosp,HarvardMedSch,Boston,MA,USA; 2 Univ ofUtahSchofMed,SaltLakeCity,UT,USA; 3 BotswanaMinistryofHlth, Gaborone,Botswana; 4 GaboronePrivateHosp,Gaborone,Botswana; 5 NatlHlthLab,Gaborone,Botswana 1:45 PM-2:45 PM Rants About HCV RAVS Themed Discussion Leader Gary P. Wang ,NorthFlorida/SouthGeorgiaVeteransHealthSystem, Gainesville,FL,US 579 Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance Wei Huang ; Alicia Newton; Arne Frantzell; Jennifer Cook; Dongmei Yang; Joseph M.Volpe; Charles M.Walworth; Jeannette M.Whitcomb; Jacqueline D. Reeves; Christos Petropoulos MonogramBioScis,SouthSanFrancisco,CA,USA 577 HCV Resistance to Daclatasvir/Sofosbuvir Across Different Genotypes in the Real Life Slim Fourati 1 ; Christophe Hezode 1 ; Alexandre Soulier 1 ; Lila Poiteau 1 ; Marion Lavert 1 ; Christophe Rodriguez 2 ; Stephane Chevaliez 1 ; Jean- Michel Pawlotsky 1 1 INSERMU955,Créteil,France; 2 InstMondordeRechercheBiomédicale INSERMU955,Créteil,France 543 Tracing the Origin of HCV NS3 Q80K Among HIV- Infected MSM in the Netherlands 1 PHServiceofAmsterdam,Amsterdam,Netherlands; 2 Academic MedCntr,Amsterdam,Netherlands; 3 UnivMedCntrUtrecht,Utrecht, Netherlands; 4 SanquinBloodSupplyFndn,Amsterdam,Netherlands; 5 Cntrof InfectiousDiseasesand ImmunologyAmsterdam,AcademicMed Cntr,Amsterdam,Netherlands 578 Polymorphisms at Codon 28 of HCV NS5A Impact NS5A Inhibitor Susceptibility Alicia Newton ; Arne Frantzell; Christos Petropoulos;Wei Huang MonogramBioScis,SouthSanFrancisco,CA,USA 580 Resistance Associated Variants: Data From the NIAID SYNERGY Trial Eleanor M.Wilson 1 ; Sarah Kattakuzhy 2 ; Hongmei Mo 3 ; Anuoluwapo Osinusi 3 ; Henry Masur 4 ; Anita Kohli 5 ; Shyam Kottilil 6 1 InstofHumanVirology,Baltimore,MD,USA; 2 InstofHumanVirology, Bethesda,MD,USA; 3 GileadScis, Inc,FosterCity,CA,USA; 4 NIH,Bethesda, MD,USA; 5 DignityHlth,St. Joseph'sHosp,Phoenix,AZ,USA; 6 Univof MarylandMedCntr,Baltimore,MD,USA Session TD-3 Themed Discussion Ballroom B/C Astrid M. Newsum 1 ; Cynthia K. Ho 2 ; Faydra I. Lieveld 3 ;Thijs J. van de Laar 4 ; JanT. van der Meer 5 ; Anne M.Wensing 3 ; Greet J. Boland 3 ; Joop E. Arends 3 ; Maria Prins 1 ; Janke Schinkel 2

Tuesday, February 23, 2016 • Oral Sessions

29

CROI 2016